Despite a reduction in total debt to $16.9 billion as of 2026Q1, the company's leverage remains elevated with a debt-to-equity ratio of 2.05 and a narrow current ratio of 1.01, indicating limited liquidity buffers.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Total Current Assets | 13.71B | 13.95B | 12.55B | 12.48B | 12.05B | 12.57B | 13.01B | 13.46B | 13.79B | 15.38B | 16.96B | 18.4B | 14.4B | 13.72B | 16.36B | 14.45B | 12.24B | 12.14B | 11.43B | 9.86B | 7.64B | 5.51B | 4.2B | 3.72B | 2.9B | 2.18B | 1.61B | 910.48M | 776.2M | 668.8M | 725.9M |
| Cash & Short-Term Investments | 3.74B | 3.56B | 3.3B | 3.23B | 2.8B | 2.17B | 2.18B | 1.98B | 1.78B | 963M | 988M | 6.95B | 2.23B | 1.04B | 2.88B | 1.1B | 1.28B | 2.25B | 1.91B | 2.88B | 2.04B | 2.21B | 1.04B | 1.38B | 1.05B | 790.14M | 424.54M | 94.4M | 49.2M | 58.6M | 69.2M |
| Cash Only | 3.74B | 3.56B | 3.3B | 3.23B | 2.8B | 2.17B | 2.18B | 1.98B | 1.78B | 963M | 988M | 6.95B | 2.23B | 1.04B | 2.88B | 1.1B | 1.25B | 2B | 1.85B | 1.49B | 1.33B | 1.28B | 784.1M | 1.06B | 809.9M | 768.92M | 420.63M | 77.18M | 47.1M | 50.9M | 61.2M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 36M | 253M | 53M | 1.39B | 712M | 935.5M | 256.8M | 322.1M | 235.7M | 21.23M | 3.9M | 17.23M | 2.1M | 7.7M | 8M |
| Accounts Receivable | 3.39B | 3.71B | 3.06B | 3.41B | 3.7B | 4.53B | 4.58B | 5.68B | 5.82B | 7.13B | 7.52B | 5.35B | 5.41B | 5.34B | 5.57B | 6.21B | 5.48B | 5.02B | 4.65B | 3.55B | 2.92B | 2.18B | 1.87B | 1.33B | 0 | 817.59M | 680.82M | 464.6M | 373.8M | 307.7M | 328.1M |
| Days Sales Outstanding | 76.14 | 78.45 | 67.49 | 78.51 | 90.39 | 104.11 | 100.37 | 122.68 | 112.71 | 116.23 | 125.37 | 99.37 | 97.37 | 95.91 | 100.1 | 123.84 | 123.98 | 131.8 | 153.21 | 137.57 | 126.85 | 151.55 | 142.56 | 148.43 | - | 143.65 | 142.01 | 132.24 | 122.27 | 100.56 | 125.56 |
| Inventory | 3.18B | 3.18B | 3.01B | 4.02B | 3.83B | 3.82B | 4.4B | 4.42B | 4.73B | 4.92B | 4.95B | 3.97B | 4.37B | 5.05B | 5.5B | 5.01B | 3.87B | 3.33B | 3.4B | 2.44B | 1.88B | 1.11B | 1.29B | 1B | 781.1M | 570.15M | 503.49M | 351.48M | 353.2M | 302.5M | 328.6M |
| Days Inventory Outstanding | 144.55 | 139.46 | 129.41 | 178.98 | 175.94 | 168.22 | 179.91 | 172.61 | 163.56 | 155.47 | 180.03 | 174.49 | 173.11 | 191.98 | 207.78 | 207.96 | 199.98 | 186.19 | 242.24 | 196.56 | 165.3 | 146.83 | 183.43 | 208.64 | 200.32 | 169.18 | 190.84 | 183.48 | 202.67 | 175.56 | 217.91 |
| Other Current Assets | 2.33B | 2.38B | 2.18B | 575M | 559M | 986M | 899M | 521M | 560M | 1.27B | 2.13B | 1.23B | 2.39B | 2.29B | 2.4B | 2.13B | 1.42B | 1.54B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 26.33B | 26.8B | 26.77B | 30.99B | 31.96B | 35.09B | 37.63B | 44.01B | 46.89B | 55.23B | 75.93B | 35.86B | 32.02B | 33.79B | 34.25B | 35.69B | 26.81B | 21.67B | 21.48B | 13.55B | 12.83B | 4.88B | 5.43B | 2.2B | 1.73B | 1.28B | 1.25B | 803.54M | 659.8M | 519.6M | 515.5M |
| Property, Plant & Equipment | 4.33B | 4.42B | 4.95B | 6.15B | 6.16B | 6.48B | 6.85B | 6.95B | 6.87B | 7.67B | 8.07B | 6.54B | 6.54B | 6.63B | 6.32B | 5.95B | 4.36B | 3.77B | 3.7B | 2.52B | 2.19B | 1.36B | 1.28B | 827.4M | 675.4M | 554.14M | 534.14M | 478.54M | 455M | 417.3M | 413.7M |
| Fixed Asset Turnover | 3.64x | 3.90x | 3.34x | 2.58x | 2.42x | 2.45x | 2.43x | 2.43x | 2.75x | 2.92x | 2.71x | 3.00x | 3.10x | 3.06x | 3.22x | 3.08x | 3.70x | 3.69x | 3.00x | 3.74x | 3.83x | 3.86x | 3.75x | 3.96x | 3.73x | 3.75x | 3.28x | 2.68x | 2.45x | 2.68x | 2.31x |
| Goodwill | 15.82B | 16B | 15.15B | 17.18B | 17.63B | 20.04B | 20.62B | 24.85B | 24.92B | 28.41B | 44.41B | 19.02B | 18.41B | 18.98B | 18.86B | 18.29B | 15.23B | 12.67B | 12.3B | 8.41B | 8.04B | 2.46B | 2.57B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 3.61B | 3.78B | 4.42B | 5.39B | 6.27B | 7.47B | 8.92B | 11.23B | 14.01B | 17.64B | 21.49B | 7.67B | 5.51B | 6.48B | 7.75B | 10.32B | 5.75B | 4.05B | 4.58B | 1.92B | 1.99B | 634.9M | 714.8M | 927M | 736.5M | 586.22M | 612.58M | 293.32M | 172.2M | 81.6M | 85.1M |
| Long-Term Investments | 0 | 0 | 0 | 8M | 0 | 0 | 0 | 0 | 58M | 25M | 88M | 1.45B | 176M | 179M | 205M | 991M | 632M | 534M | 425M | 0 | 613M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 376M | 404.99M | 462M | 462M | 441M | 515M | 538M | 591M | 673M | 907M | 1.15B | 2.62B | 1.57B | 1.7B | 1.34B | 0 | 0 | 0 | 0 | 712M | 613M | 410.6M | 843.6M | 445.1M | 313.5M | 141.91M | 100.05M | 31.68M | 32.6M | 20.7M | 16.7M |
| Total Assets | 40.04B | 40.75B | 39.33B | 43.48B | 44.01B | 47.67B | 50.64B | 57.47B | 60.68B | 70.61B | 92.89B | 54.26B | 46.42B | 47.51B | 50.61B | 50.14B | 39.05B | 33.81B | 32.9B | 23.41B | 20.47B | 10.39B | 9.63B | 5.92B | 4.63B | 3.46B | 2.86B | 1.71B | 1.44B | 1.19B | 1.24B |
| Asset Turnover | 0.43x | 0.42x | 0.42x | 0.36x | 0.34x | 0.33x | 0.33x | 0.29x | 0.31x | 0.32x | 0.24x | 0.36x | 0.44x | 0.43x | 0.40x | 0.37x | 0.41x | 0.41x | 0.34x | 0.40x | 0.41x | 0.51x | 0.50x | 0.55x | 0.54x | 0.60x | 0.61x | 0.75x | 0.78x | 0.94x | 0.77x |
| Asset Growth % | 0.37% | 3.61% | -9.55% | -1.21% | -7.67% | -5.87% | -11.88% | -5.29% | -14.06% | -23.98% | 71.2% | 16.89% | -2.29% | -6.13% | 0.93% | 28.4% | 15.5% | 2.75% | 40.54% | 14.37% | 97.08% | 7.84% | 62.82% | 27.86% | 33.72% | 21.17% | 66.6% | 19.36% | 20.83% | -4.27% | 42.48% |
| Total Current Liabilities | 13.53B | 13.46B | 12.8B | 12.25B | 11.47B | 11.03B | 13.16B | 13.67B | 14.32B | 17.92B | 18.52B | 13.01B | 12.29B | 11.96B | 12.89B | 13.85B | 9.89B | 7.6B | 8.48B | 5.37B | 4.07B | 2.26B | 2.2B | 1.69B | 1.52B | 738.12M | 783.75M | 537.57M | 537.6M | 427.6M | 521.7M |
| Accounts Payable | 2.6B | 2.53B | 2.2B | 2.6B | 1.89B | 1.69B | 1.76B | 1.72B | 1.85B | 2.07B | 2.16B | 1.92B | 3.17B | 3.32B | 3.4B | 1.13B | 2.51B | 2.68B | 2.26B | 1.38B | 2.56B | 559.77M | 1.64B | 1.05B | 785.7M | 531.6M | 161.84M | 114.45M | 208.6M | 182.4M | 180.5M |
| Days Payables Outstanding | 109.5 | 111.03 | 94.81 | 115.82 | 86.61 | 74.29 | 71.75 | 67.06 | 64.06 | 65.33 | 78.39 | 84.39 | 125.59 | 126.02 | 128.21 | 47.01 | 129.8 | 149.95 | 161.55 | 111.41 | 224.95 | 73.77 | 234.44 | 218.21 | 201.5 | 157.74 | 61.34 | 59.75 | 119.7 | 105.86 | 119.7 |
| Short-Term Debt | 2.61B | 1.82B | 1.78B | 1.67B | 2.11B | 1.43B | 3.19B | 2.35B | 2.22B | 3.65B | 3.28B | 1.58B | 1.76B | 1.8B | 3.01B | 4.28B | 1.43B | 1.3B | 2.91B | 1.84B | 742M | 375.5M | 560M | 644.2M | 738.5M | 206.52M | 341.52M | 276.26M | 324.5M | 239.8M | 341.2M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 7.29B | 0 | 9.45B | 11.44B | 725M | 735M | 993M | 1.08B | 1.14B | 2.61B | 1.35B | 1.74B | 1.72B | 0 | 486M | -741.39M | 212.3M | 34.6M | 43.7M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 7.77B | 8.37B | 6.02B | 5.2B | 5.32B | 5.71B | 246M | 7.74B | 9.38B | 11.66B | 12.2B | 7.82B | 3.38B | 3.72B | 6.49B | 5.78B | 7.29B | 5.36B | 5.05B | 2.15B | 0 | 1.33B | -100K | 0 | 0 | 0 | 280.39M | 146.86M | 4.5M | 5.4M | 0 |
| Current Ratio | 1.01x | 1.04x | 0.98x | 1.02x | 1.05x | 1.14x | 0.99x | 0.98x | 0.96x | 0.86x | 0.92x | 1.41x | 1.17x | 1.15x | 1.27x | 1.04x | 1.24x | 1.60x | 1.35x | 1.84x | 1.88x | 2.44x | 1.91x | 2.19x | 1.90x | 2.95x | 2.05x | 1.69x | 1.44x | 1.56x | 1.39x |
| Quick Ratio | 0.78x | 0.80x | 0.75x | 0.69x | 0.72x | 0.79x | 0.65x | 0.66x | 0.63x | 0.58x | 0.65x | 1.11x | 0.82x | 0.72x | 0.84x | 0.68x | 0.85x | 1.16x | 0.95x | 1.38x | 1.42x | 1.94x | 1.32x | 1.60x | 1.39x | 2.18x | 1.41x | 1.04x | 0.79x | 0.86x | 0.76x |
| Cash Conversion Cycle | 111.2 | 106.87 | 102.09 | 141.67 | 179.71 | 198.05 | 208.53 | 228.23 | 212.2 | 206.37 | 227.01 | 189.47 | 144.9 | 161.87 | 179.67 | 284.78 | 194.17 | 168.04 | 233.9 | 222.72 | 67.2 | 224.61 | 91.55 | 138.86 | - | 155.09 | 271.51 | 255.97 | 205.24 | 170.26 | 223.77 |
| Total Non-Current Liabilities | 18.28B | 19.38B | 20.81B | 23.11B | 23.94B | 25.39B | 26.41B | 28.73B | 30.57B | 33.95B | 39.38B | 11.33B | 10.78B | 12.91B | 14.85B | 13.95B | 7.16B | 6.95B | 8.06B | 4.28B | 5.22B | 2.08B | 2.03B | 924.9M | 1.27B | 1.34B | 918.88M | 434.15M | 238.8M | 148M | 184.5M |
| Long-Term Debt | 14.02B | 15.27B | 16B | 18.16B | 19.1B | 21.62B | 22.73B | 24.56B | 26.7B | 28.83B | 32.52B | 8.38B | 8.57B | 10.39B | 11.71B | 10.24B | 4.1B | 3.49B | 3.65B | 3.35B | 2.13B | 1.77B | 0 | 815.4M | 0 | 1.25B | 813.89M | 391.42M | 201.7M | 129.9M | 161.1M |
| Capital Lease Obligations | 1.15B | 288M | 296M | 320M | 349M | 416M | 479M | 435M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -208M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 1.41B | 296M | 483M | 606M | 548M | 784M | 964M | 1.1B | 2.14B | 3.28B | 5.21B | 1.75B | 1.1B | 1.25B | 1.85B | 2.61B | 2.05B | 1.74B | 1.72B | 459M | 486M | 219.3M | 212.3M | 34.6M | 43.7M | 39.03M | 64.87M | 31.69M | 33.2M | 13.8M | 14.5M |
| Other Non-Current Liabilities | 3.71B | 3.52B | 4.03B | 4.02B | 3.94B | 2.58B | 2.24B | 2.64B | 1.73B | 1.84B | 1.64B | 1.2B | 1.11B | 1.27B | 1.29B | 1.11B | 790M | 2.21B | 2.69B | 475M | 3.1B | 84.4M | 2.03B | 74.9M | 1.27B | 53.28M | 40.12M | 11.04M | 3.9M | 4.3M | 8.9M |
| Total Liabilities | 31.81B | 32.83B | 33.61B | 35.35B | 35.41B | 36.42B | 39.58B | 42.41B | 44.89B | 51.87B | 57.9B | 24.33B | 23.07B | 24.87B | 27.74B | 27.8B | 17.05B | 14.55B | 16.54B | 9.65B | 9.29B | 4.34B | 4.23B | 2.62B | 2.79B | 2.08B | 1.7B | 971.72M | 776.4M | 575.6M | 706.2M |
| Total Debt | 16.91B | 17.38B | 18.08B | 20.15B | 21.56B | 23.46B | 26.4B | 27.34B | 28.92B | 32.48B | 35.8B | 9.97B | 10.33B | 12.19B | 14.72B | 14.52B | 5.53B | 6.34B | 8.44B | 5.19B | 5.33B | 2.15B | 2.07B | 1.46B | 1.9B | 1.45B | 1.16B | 667.68M | 526.2M | 369.7M | 502.3M |
| Net Debt | 13.17B | 13.83B | 14.78B | 16.93B | 18.76B | 21.29B | 24.22B | 25.37B | 27.13B | 31.51B | 34.81B | 3.02B | 8.1B | 11.15B | 11.84B | 13.42B | 4.28B | 4.34B | 6.59B | 3.7B | 4B | 873.2M | 1.29B | 402.3M | 1.09B | 684.48M | 734.78M | 590.5M | 479.1M | 318.8M | 441.1M |
| Debt / Equity | 2.05x | 2.20x | 3.16x | 2.48x | 2.51x | 2.09x | 2.39x | 1.82x | 1.83x | 1.73x | 1.02x | 0.33x | 0.44x | 0.54x | 0.64x | 0.65x | 0.25x | 0.33x | 0.52x | 0.38x | 0.48x | 0.36x | 0.38x | 0.44x | 1.04x | 1.05x | 1.00x | 0.90x | 0.80x | 0.60x | 0.94x |
| Debt / EBITDA | 5.14x | 5.50x | 23.91x | 12.71x | - | 7.70x | - | 21.38x | 141.05x | - | 9.81x | 2.14x | 1.89x | 3.70x | 3.76x | 3.47x | 1.14x | 1.91x | 5.15x | 1.78x | 4.32x | 1.38x | 2.60x | 1.45x | 3.06x | 3.09x | 3.40x | 2.50x | 2.58x | 1.64x | 2.90x |
| Net Debt / EBITDA | 4.00x | 4.38x | 19.55x | 10.67x | - | 6.99x | - | 19.83x | 132.36x | - | 9.54x | 0.65x | 1.48x | 3.39x | 3.03x | 3.21x | 0.88x | 1.31x | 4.02x | 1.27x | 3.24x | 0.56x | 1.62x | 0.40x | 1.76x | 1.46x | 2.16x | 2.21x | 2.35x | 1.41x | 2.55x |
| Interest Coverage | 2.51x | 2.34x | 3.58x | 0.39x | -2.40x | 3.46x | 4.05x | 2.84x | -1.88x | -19.66x | 1.03x | 5.64x | 14.27x | 5.55x | - | 20.85x | 17.10x | 10.46x | 3.60x | - | 0.78x | 298.18x | 0.98x | - | 31.19x | 8.73x | 1.94x | 6.03x | 3.03x | 4.05x | 2.81x |
| Total Equity | 8.23B | 7.91B | 5.72B | 8.13B | 8.6B | 11.24B | 11.06B | 15.06B | 15.79B | 18.75B | 34.99B | 29.93B | 23.36B | 22.64B | 22.87B | 22.34B | 22B | 19.26B | 16.36B | 13.76B | 11.18B | 6.05B | 5.4B | 3.3B | 1.83B | 1.38B | 1.15B | 742.3M | 659.6M | 612.8M | 535.2M |
| Equity Growth % | 87.43% | 38.35% | -29.61% | -5.49% | -23.53% | 1.65% | -26.57% | -4.63% | -15.74% | -46.43% | 16.93% | 28.14% | 3.18% | -1.01% | 2.35% | 1.55% | 14.24% | 17.72% | 18.9% | 23.11% | 84.73% | 12.05% | 63.82% | 79.69% | 32.65% | 19.94% | 55.33% | 12.54% | 7.64% | 14.5% | 31.31% |
| Book Value per Share | 6.98 | 6.75 | 5.06 | 7.26 | 7.75 | 10.16 | 10.10 | 13.81 | 15.47 | 18.45 | 36.41 | 34.64 | 27.22 | 26.63 | 26.19 | 25.02 | 23.89 | 21.49 | 19.95 | 16.58 | 13.88 | 8.88 | 7.85 | 5.59 | 3.27 | 2.53 | 2.21 | 1.51 | 1.35 | 1.25 | 1.09 |
| Total Shareholders' Equity | 8.23B | 7.91B | 5.37B | 7.51B | 7.8B | 10.28B | 10.03B | 13.97B | 14.71B | 17.36B | 33.34B | 29.77B | 23.31B | 22.57B | 22.77B | 22.2B | 21.95B | 19.22B | 16.3B | 13.72B | 11.14B | 6.04B | 5.39B | 3.29B | 1.83B | 1.38B | 1.15B | 742.28M | 658.8M | 612M | 534.2M |
| Common Stock | -4.07B | 58M | 58M | 57M | 57M | 57M | 57M | 56M | 56M | 54M | 54M | 52M | 50M | 50M | 50M | 50M | 49M | 49M | 48M | 46M | 46M | 42.6M | 42.1M | 34.3M | 33.9M | 31.03M | 31.03M | 183.62M | 175.4M | 173.1M | 170.2M |
| Retained Earnings | -13.39B | -13.76B | -15.17B | -13.53B | -12.97B | -10.53B | -10.95B | -6.96B | -5.96B | -3.8B | 13.61B | 14.85B | 14.44B | 12.54B | 12.35B | 11.28B | 9.32B | 6.66B | 5.29B | 5.04B | 3.4B | 3.08B | 2.17B | 1.96B | 1.35B | 970.42M | 728.34M | 603.96M | 506.1M | 456.7M | 376.4M |
| Treasury Stock | 0 | -4.13B | -4.13B | -4.13B | -4.13B | -4.13B | -4.13B | -4.13B | -4.14B | -4.15B | -4.19B | -4.23B | -3.95B | -3.56B | -3.08B | -1.92B | -1.02B | -924M | -924M | -982M | -830M | -617.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -2.51B | -2.39B | -3.15B | -2.7B | -2.84B | -2.68B | -2.4B | -2.31B | -2.46B | -1.85B | -3.16B | -1.96B | -1.34B | -91M | -17M | -589M | 350M | 555M | 390M | 1.36B | 651M | -471.7M | 140.4M | 135.5M | -31.7M | -101.3M | -84.22M | -25.61M | -19.1M | -15.4M | -15.9M |
| Minority Interest | 4M | 4M | 347M | 620M | 794M | 966M | 1.03B | 1.09B | 1.09B | 1.39B | 1.66B | 158M | 42M | 71M | 99M | 148M | 55M | 37M | 60M | 36M | 35M | 8M | 10.9M | 6.7M | 4.9M | 2.16M | 1.64M | 17K | 800K | 800K | 1M |
High Debt Refinancing Burden
As reported in recent financial statements, Teva has successfully reduced its total debt from $20.2 billion in 2023Q4 to $16.9 billion by 2026Q1, yet the company's equity base remains pressured by a persistent negative retained earnings balance of $13.4 billion, signaling a long-term recovery trajectory.
The reduction in debt suggests a disciplined focus on balance sheet repair, which is essential given the company's historical over-leverage. However, the persistent negative retained earnings indicate that past impairment charges and legal settlements continue to weigh heavily on the company's book value, limiting its financial flexibility.
Based on quarterly data, Teva's debt-to-equity ratio has improved from a peak of 3.16 in 2024Q4 to 2.05 in 2026Q1, though this metric remains elevated compared to industry peers, suggesting that the company's capital structure remains highly sensitive to interest rate fluctuations and refinancing requirements.
While the downward trend in the D/E ratio is a positive development, the absolute level of debt remains a significant burden that necessitates consistent cash flow generation. Investors should monitor whether the company can maintain this deleveraging pace without sacrificing necessary R&D investment in its specialty pipeline.
According to recent SEC filings, Teva's current ratio has hovered near parity, moving from 1.02 in 2023Q4 to 1.01 in 2026Q1, which indicates a narrow margin of safety for meeting short-term obligations and leaves little room for operational shocks or unexpected legal outflows.
The proximity of the current ratio to 1.0 suggests that the company is operating with minimal working capital headroom. This tight liquidity position implies that any disruption in generic cash flows or a sudden spike in operational costs could force the company to rely on external financing, which may be costly.
As disclosed in financial filings, Teva carries $15.8 billion in goodwill as of 2026Q1, representing nearly 40% of total assets, which suggests that the balance sheet remains vulnerable to future non-cash impairment charges if the performance of acquired generic assets continues to face pricing pressure.
The high concentration of goodwill relative to total assets is a critical distortion that masks the true economic value of the company's tangible manufacturing base. If the generic market environment fails to stabilize, these intangible assets may require further write-downs, which would further erode the already thin equity base.
Quick answers to the most common questions about buying TEVA stock.
As of 2025, Teva Pharmaceutical Industries Limited (TEVA) had total assets of $40.75B including $13.95B in current assets.
Teva Pharmaceutical Industries Limited (TEVA) carries total debt of $17.38B, offset by $3.56B in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Teva Pharmaceutical Industries Limited (TEVA) has total shareholders' equity (book value) of $7.91B ($6.75 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Teva Pharmaceutical Industries Limited (TEVA) reported a current ratio of 1.04x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.